Bicara Therapeutics Inc. (BCAX) Cash Flow Statement
Bicara Therapeutics Inc. (BCAX) generated -$134.8M of operating cash flow over the twelve months to 2026-06-30, spent $400000 on capital expenditure and had free cash flow of -$135.2M, according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
BCAXBicara Therapeutics Inc.Follow BCAX — free
—
Price chart with a free account
- Market cap
- 1.1B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 17 Nov, in 24 days
| Line | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|
| Operating cash flow | -74.8 | -106.8 | -134.8 | |
| Capital expenditure | 0.1 | 0.3 | -0.4 | |
| Free cash flow | -74.8 | -107.1 | -135.2 | |
| Stock-based compensation | 7.4 | 15.0 | — |
USD millions · SEC XBRL
Bicara Therapeutics Inc. — questions
- What is Bicara Therapeutics Inc.'s operating cash flow?
- -$134.8M over the twelve months to 2026-06-30.
- How much does Bicara Therapeutics Inc. spend on capital expenditure?
- $400000 over the twelve months to 2026-06-30.
- What is Bicara Therapeutics Inc.'s free cash flow?
- -$135.2M over the twelve months to 2026-06-30: operating cash flow minus capital expenditure.
Every figure on this page comes from Bicara Therapeutics Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.